Akyuz Muhammet, Yazici Pınar, Dural Cem, Yigitbas Hakan, Okoh Alexis, Bucak Emre, McNamara Michael, Singh Arun, Berber Eren
Departments of Endocrine and General Surgery, Cleveland Clinic, 9500 Euclid Avenue/F20, Cleveland, OH, 44195, USA.
Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
Surg Endosc. 2016 Jun;30(6):2567-71. doi: 10.1007/s00464-015-4527-9. Epub 2015 Aug 27.
Although uveal melanoma is a rare disease, its metastasis to the liver is associated with a poor survival. The aim of this study is to analyze the survival after surgical treatment of uveal melanoma metastases to the liver.
Within 15 years, 44 patients with uveal melanoma metastases to the liver were managed at a single center. Medical records were reviewed to identify patients who underwent surgical treatment of their liver disease. Clinical and oncologic results were compared to those patients who were managed otherwise. T test, Chi-square test, and Kaplan-Meier survival analyses were performed.
There were 16 patients who underwent surgical treatment (laparoscopic liver resection, n = 2 and laparoscopic radiofrequency ablation, n = 14), compared to 28 patients who received systemic therapy. The groups were similar regarding demographics and size of primary tumor. The interval between diagnoses of primary tumor and liver metastases was longer for the surgical group (58 vs 22 months, respectively, p = 0.010). Although the dominant liver tumor size was similar, the average number of liver tumors was 4 in the surgical group and 10 in the systemic therapy group (p < 0.0001). The median survival after diagnosis of liver metastases was 35 months in the surgical group and 15 months in the systemic therapy group (p ≤ 0.0001). Five-year survival was zero in the systemic therapy group and 22 % in the surgical group.
This study shows that surgical treatment of liver metastases in selected patients with uveal melanoma, who have limited liver tumor burden and a long interval to metastases development, may result in long-term survival.
尽管葡萄膜黑色素瘤是一种罕见疾病,但其转移至肝脏与生存率低相关。本研究的目的是分析葡萄膜黑色素瘤肝转移手术治疗后的生存率。
在15年期间,单一中心管理了44例葡萄膜黑色素瘤肝转移患者。回顾病历以确定接受肝脏疾病手术治疗的患者。将临床和肿瘤学结果与采用其他治疗方式的患者进行比较。进行了t检验、卡方检验和Kaplan-Meier生存分析。
16例患者接受了手术治疗(腹腔镜肝切除术2例,腹腔镜射频消融术14例),28例患者接受了全身治疗。两组在人口统计学和原发肿瘤大小方面相似。手术组从原发肿瘤诊断到肝转移的间隔时间更长(分别为58个月和22个月,p = 0.010)。尽管主要肝肿瘤大小相似,但手术组肝肿瘤的平均数量为4个,全身治疗组为10个(p < 0.0001)。肝转移诊断后的中位生存期手术组为35个月,全身治疗组为15个月(p≤0.0001)。全身治疗组的5年生存率为零,手术组为22%。
本研究表明,对选定的葡萄膜黑色素瘤肝转移患者进行手术治疗,这些患者肝肿瘤负荷有限且转移发生间隔时间长,可能会带来长期生存。